Literature DB >> 3041509

Squamous differentiation in carcinoma of the endometrium: a critical appraisal of adenoacanthoma and adenosquamous carcinoma.

R J Zaino1, R J Kurman.   

Abstract

Although squamous differentiation within endometrial carcinomas has long been recognized by pathologists, its biologic significance has been the subject of continued debate. While some authors have found a worsened prognosis for women who have tumors with squamous elements, others have reported the prognosis to be better than conventional endometrial adenocarcinomas. Persisting confusion and disagreement about the use of the terms adenoacanthoma and adenosquamous carcinoma have complicated the issue. In this article we review the literature on the pathogenesis of squamous differentiation in the endometrium and discuss the histologic features, prevalence, and biologic behavior of adenocarcinoma with squamous differentiation. We conclude that keratin is a constituent of normal and neoplastic endometrial epithelial cells, and that overt squamous differentiation occurs by a mechanism that is currently unknown. Squamous differentiation is present in about 25% of endometrial adenocarcinomas, a frequency that appears to have been constant for the past 50 years. The squamous component of endometrial carcinomas may histologically appear benign, malignant, or indeterminant, and in the majority of instances closely parallels the differentiation of the glandular component. Endometrial adenocarcinomas with malignant-appearing squamous elements usually have poorly differentiated glandular components and have a prognosis identical to that of poorly differentiated adenocarcinoma without squamous differentiation. Endometrial adenocarcinomas with benign-appearing squamous elements are usually associated with well-differentiated glandular components and have a prognosis identical to that of typical well-differentiated adenocarcinoma. Some endometrial adenocarcinomas contain foci of squamous differentiation that appear neither clearly benign nor malignant. These often are associated with moderately differentiated glandular components; the prognosis for these women is not yet clearly defined. At the present time we are unable to attribute any prognostic significance to the presence of squamous differentiation in endometrial carcinomas. Because of the confusion and semantic arguments that revolve about the use of the terms adenoacanthoma and adenosquamous carcinomas, we recommend that those terms be abandoned and be replaced by the single term adenocarcinoma with squamous differentiation. As for any other endometrial tumor, the pathologist should provide information on histological grade, depth of myometrial invasion, and presence of vascular involvement or spread to the cervix in order to guide the gynecologist in determining appropriate therapy.

Entities:  

Mesh:

Year:  1988        PMID: 3041509

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  8 in total

1.  Squamous morules are functionally inert elements of premalignant endometrial neoplasia.

Authors:  Ming-Chieh Lin; Lesley Lomo; Jan P A Baak; Charis Eng; Tan A Ince; Christopher P Crum; George L Mutter
Journal:  Mod Pathol       Date:  2008-09-19       Impact factor: 7.842

2.  A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response.

Authors:  Hao-Dong Li; Changzheng Lu; He Zhang; Qing Hu; Junqiu Zhang; Ileana C Cuevas; Subhransu S Sahoo; Mitzi Aguilar; Elizabeth G Maurais; Shanrong Zhang; Xiaojing Wang; Esra A Akbay; Guo-Min Li; Bo Li; Prasad Koduru; Peter Ly; Yang-Xin Fu; Diego H Castrillon
Journal:  JCI Insight       Date:  2020-07-23

3.  Squamous differentiation portends poor prognosis in low and intermediate-risk endometrioid endometrial cancer.

Authors:  Diocesio Alves Pinto de Andrade; Vinicius Duval da Silva; Graziela de Macedo Matsushita; Marcos Alves de Lima; Marcelo de Andrade Vieira; Carlos Eduardo Mattos Cunha Andrade; Ronaldo Luís Schmidt; Rui Manuel Reis; Ricardo Dos Reis
Journal:  PLoS One       Date:  2019-10-10       Impact factor: 3.240

4.  Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition.

Authors:  Ileana C Cuevas; Subhransu S Sahoo; Ashwani Kumar; He Zhang; Jill Westcott; Mitzi Aguilar; Jeremy D Cortez; Stephanie A Sullivan; Chao Xing; D Neil Hayes; Rolf A Brekken; Victoria L Bae-Jump; Diego H Castrillon
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-26       Impact factor: 11.205

5.  Reliable Identification of Endometrial Precancers Through Combined Pax2, β-Catenin, and Pten Immunohistochemistry.

Authors:  Mitzi Aguilar; Hao Chen; Glorimar Rivera-Colon; Shuang Niu; Kelley Carrick; Katja Gwin; Ileana C Cuevas; Subhransu S Sahoo; Hao-Dong Li; Song Zhang; Wenxin Zheng; Elena Lucas; Diego H Castrillon
Journal:  Am J Surg Pathol       Date:  2022-03-01       Impact factor: 6.394

6.  Promoter-level transcriptome in primary lesions of endometrial cancer identified biomarkers associated with lymph node metastasis.

Authors:  Emiko Yoshida; Yasuhisa Terao; Noriko Hayashi; Kaoru Mogushi; Atsushi Arakawa; Yuji Tanaka; Yosuke Ito; Hiroko Ohmiya; Yoshihide Hayashizaki; Satoru Takeda; Masayoshi Itoh; Hideya Kawaji
Journal:  Sci Rep       Date:  2017-10-26       Impact factor: 4.379

7.  Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis.

Authors:  Jake J Reske; Mike R Wilson; Jeanne Holladay; Rebecca A Siwicki; Hilary Skalski; Shannon Harkins; Marie Adams; John I Risinger; Galen Hostetter; Ken Lin; Ronald L Chandler
Journal:  PLoS Genet       Date:  2021-12-23       Impact factor: 5.917

8.  The impact of Ki-67 index, squamous differentiation, and several clinicopathologic parameters on the recurrence of low and intermediate-risk endometrial cancer.

Authors:  Birol Ocak; Fatma Öz Atalay; Ahmet Bilgehan Sahin; Mine Ozsen; Bahar Dakiki; Seray Türe; Merve Mesohorli; Hikmet Utku Odman; Özgür Tanrıverdi; Gökhan Ocakoğlu; Mehmet Bayrak; Hakan Ozan; Candan Demiröz; Seda Sali; Sibel Oyucu Orhan; Adem Deligönül; Erdem Cubukcu; Türkkan Evrensel
Journal:  Bosn J Basic Med Sci       Date:  2021-02-18       Impact factor: 3.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.